Alzheimer’s disease is a devastating neurodegenerative condition that exerts a significant global burden. Despite recent efforts, disease modifying therapies remain extremely limited, with a tremendous proportion of patients having to rely on symptomatic treatment only. Epidemiological and pathological overlaps exist between Alzheimer’s disease and diabetes mellitus type 2, with people with diabetes mellitus type 2 at a significantly increased risk of developing Alzheimer’s disease in the future. Incretin mimetics, also known as GLP-1/GIP receptor agonists, are useful tools licensed for the treatment of diabetes mellitus type 2 which have recently been the subject of news coverage for their off-label use as weight loss medications. Emerging evidence highlights the possible neuroprotective function of incretin mimetics in models of Alzheimer’s disease as well as in clinical studies. This review details the pre-clinical and clinical studies that have explored the effectiveness of incretin mimetics to alleviate Alzheimer’s disease associated pathology and cognitive impairment, while also highlighting the progress made to examine the effectiveness of these molecules in Parkinson’s disease. Should clinical trials prove effective, incretin mimetics may be able to be repurposed and become useful novel tools as disease-modifying treatments for Alzheimer’s disease and other neurodegenerative diseases.
LanctotKL, Hviid Hahn-PedersenJ, EichingerCS, FreemanC, ClarkA, TarazonaLRS, CummingsJ (2024) Burden of illness in people with Alzheimer’s disease: A systematic review of epidemiology, comorbidities and mortality. J Prev Alzheimers Dis11, 97–107.
2.
TayLX, OngSC, TayLJ, NgT, ParumasivamT (2024) Economic burden of Alzheimer’s disease: A systematic review. Value Health Reg Issues40, 1–12.
3.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCRJr., KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
4.
Serrano-PozoA, FroschMP, MasliahE, HymanBT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med1, a006189.
AshleighT, SwerdlowRH, BealMF (2023) The role of mitochondrial dysfunction in Alzheimer’s disease pathogenesis. Alzheimers Dement19, 333–342.
9.
KhanMAB, HashimMJ, KingJK, GovenderRD, MustafaH, Al KaabiJ (2020) Epidemiology of type 2 diabetes - global burden of disease and forecasted trends. J Epidemiol Glob Health10, 107–111.
10.
DeFronzoRA (2004) Pathogenesis of type 2 diabetes mellitus. Med Clin North Am88, 787–835,ix.
11.
HavrankovaJ, SchmechelD, RothJ, BrownsteinM (1978) Identification of insulin in rat brain. Proc Natl Acad Sci U S A75, 5737–5741.
12.
HoyerS, HennebergN, KnappS, LannertH, MartinE (1996) Brain glucose metabolism is controlled by amplification and desensitization of the neuronal insulin receptor. Ann N Y Acad Sci777, 374–379.
13.
CsajbokEA, TamasG (2016) Cerebral cortex: A target and source of insulin?Diabetologia59, 1609–1615.
14.
PetrovD, PedrosI, ArtiachG, SuredaFX, BarrosoE, PallasM, CasadesusG, Beas-ZarateC, CarroE, FerrerI, Vazquez-CarreraM, FolchJ, CaminsA (2015) High-fat diet-induced deregulation of hippocampal insulin signaling and mitochondrial homeostasis deficiences contribute to Alzheimer disease pathology in rodents. Biochim Biophys Acta1852, 1687–1699.
15.
ReaganLP (2005) Neuronal insulin signal transduction mechanisms in diabetes phenotypes. Neurobiol Aging26(Suppl 1), 56–59.
16.
McNayEC, RecknagelAK (2011) Brain insulin signaling: A key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes. Neurobiol Learn Mem96, 432–442.
17.
McNayEC, OngCT, McCrimmonRJ, CresswellJ, BoganJS, SherwinRS (2010) Hippocampal memory processes are modulated by insulin and high-fat-induced insulin resistance. Neurobiol Learn Mem93, 546–553.
18.
WangY, YangY, LiuY, GuoA, ZhangY (2022) Cognitive impairments in type 1 diabetes mellitus model mice are associated with synaptic protein disorders. Neurosci Lett777, 136587.
19.
CraftS, PeskindE, SchwartzMW, SchellenbergGD, RaskindM, PorteDJr (1998) Cerebrospinal fluid and plasma insulin levels in Alzheimer’s disease: Relationship to severity of dementia and apolipoprotein E genotype. Neurology50, 164–168.
20.
OttA, StolkRP, van HarskampF, PolsHA, HofmanA, BretelerMM (1999) Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology53, 1937–1942.
21.
BiesselsGJ, StaekenborgS, BrunnerE, BrayneC, ScheltensP (2006) Risk of dementia in diabetes mellitus: A systematic review. Lancet Neurol5, 64–74.
22.
OharaT, DoiY, NinomiyaT, HirakawaY, HataJ, IwakiT, KanbaS, KiyoharaY (2011) Glucose tolerance status and risk of dementia in the community: The Hisayama study. Neurology77, 1126–1134.
23.
JansonJ, LaedtkeT, ParisiJE, O’BrienP, PetersenRC, ButlerPC (2004) Increased risk of type 2 diabetes in Alzheimer disease. Diabetes53, 474–481.
24.
ArvanitakisZ, WilsonRS, BieniasJL, EvansDA, BennettDA (2004) Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol61, 661–666.
25.
PeilaR, RodriguezBL, LaunerLJ, Honolulu-Asia AgingS (2002) Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes51, 1256–1262.
26.
XuWL, QiuCX, WahlinA, WinbladB, FratiglioniL (2004) Diabetes mellitus and risk of dementia in the Kungsholmen project: A 6-year follow-up study. Neurology63, 1181–1186.
27.
Schnaider BeeriM, GoldbourtU, SilvermanJM, NoyS, SchmeidlerJ, Ravona-SpringerR, SverdlickA, DavidsonM (2004) Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology63, 1902–1907.
28.
RonnemaaE, ZetheliusB, SundelofJ, SundstromJ, Degerman-GunnarssonM, BerneC, LannfeltL, KilanderL (2008) Impaired insulin secretion increases the risk of Alzheimer disease. Neurology71, 1065–1071.
29.
ChengG, HuangC, DengH, WangH (2012) Diabetes as a risk factor for dementia and mild cognitive impairment: A meta-analysis of longitudinal studies. Intern Med J42, 484–491.
KreymannB, WilliamsG, GhateiMA, BloomSR (1987) Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet2, 1300–1304.
32.
DruckerDJ, AsaS (1988) Glucagon gene expression in vertebrate brain. J Biol Chem263, 13475–13478.
33.
MayoKE, MillerLJ, BatailleD, DalleS, GokeB, ThorensB, DruckerDJ (2003) International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev55, 167–194.
34.
WheelerMB, LuM, DillonJS, LengXH, ChenC, BoydAE3rd (1993) Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C. Endocrinology133, 57–62.
35.
Montrose-RafizadehC, AvdoninP, GarantMJ, RodgersBD, KoleS, YangH, LevineMA, SchwindingerW, BernierM (1999) Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells. Endocrinology140, 1132–1140.
36.
ManHY, WangQ, LuWY, JuW, AhmadianG, LiuL, D’SouzaS, WongTP, TaghibiglouC, LuJ, BeckerLE, PeiL, LiuF, WymannMP, MacDonaldJF, WangYT (2003) Activation of PI3-kinase is required for AMPA receptor insertion during LTP of mEPSCs in cultured hippocampal neurons. Neuron38, 611–624.
37.
HoriuchiJ, YamazakiD, NaganosS, AigakiT, SaitoeM (2008) Protein kinase A inhibits a consolidated form of memory in Drosophila. Proc Natl Acad Sci U S A105, 20976–20981.
38.
FaissnerA, HeckN, DobbertinA, GarwoodJ (2006) DSD-1-proteoglycan/phosphacan and receptor protein tyrosine phosphatase-beta isoforms during development and regeneration of neural tissues. In Brain Repair, BährM, ed. Springer US, Boston, MA, pp. 25–53.
39.
DuringMJ, CaoL, ZuzgaDS, FrancisJS, FitzsimonsHL, JiaoX, BlandRJ, KlugmannM, BanksWA, DruckerDJ, HaileCN (2003) Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med9, 1173–1179.
40.
MortensenK, ChristensenLL, HolstJJ, OrskovC (2003) GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept114, 189–196.
41.
NybergJ, AndersonMF, MeisterB, AlbornAM, StromAK, BrederlauA, IllerskogAC, NilssonO, KiefferTJ, HietalaMA, RickstenA, ErikssonPS (2005) Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation. J Neurosci25, 1816–1825.
42.
NybergJ, JacobssonC, AndersonMF, ErikssonPS (2007) Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain. J Neurosci Res85, 2099–2119.
43.
SuranM (2023) As Ozempic’s popularity soars, here’s what to know about semaglutide and weight loss. JAMA329, 1627–1629.
44.
RyanDH, LingvayI, DeanfieldJ, KahnSE, BarrosE, BurgueraB, ColhounHM, CercatoC, DickerD, HornDB, HovinghGK, JeppesenOK, KokkinosA, LincoffAM, MeyhoferSM, OralTK, PlutzkyJ, van BeekAP, WildingJPH, KushnerRF (2024) Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med30, 2049–2057.
45.
LincoffAM, Brown-FrandsenK, ColhounHM, DeanfieldJ, EmersonSS, EsbjergS, Hardt-LindbergS, HovinghGK, KahnSE, KushnerRF, LingvayI, OralTK, MichelsenMM, PlutzkyJ, TornoeCW, RyanDH, InvestigatorsST (2023) Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med389, 2221–2232.
46.
GilbertMP, PratleyRE (2020) GLP-1 Analogs and DPP-4 inhibitors in type 2 diabetes therapy: Review of head-to-head clinical trials. Front Endocrinol (Lausanne)11, 178.
47.
NauckMA, QuastDR, WefersJ, MeierJJ (2021) GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab46, 101102.
48.
LiY, DuffyKB, OttingerMA, RayB, BaileyJA, HollowayHW, TweedieD, PerryT, MattsonMP, KapogiannisD, SambamurtiK, LahiriDK, GreigNH (2010) GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer’s disease. J Alzheimers Dis19, 1205–1219.
KhalilnezhadA, TaskiranD (2019) The investigation of protective effects of glucagon-like peptide-1 (GLP-1) analogue exenatide against glucose and fructose-induced neurotoxicity. Int J Neurosci129, 481–491.
51.
RachmanyL, TweedieD, LiY, RubovitchV, HollowayHW, MillerJ, HofferBJ, GreigNH, PickCG (2013) Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice. Age (Dordr)35, 1621–1636.
52.
PerryT, LahiriDK, ChenD, ZhouJ, ShawKT, EganJM, GreigNH (2002) A novel neurotrophic property of glucagon-like peptide 1: A promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther300, 958–966.
53.
BombaM, GranzottoA, CastelliV, MassettiN, SilvestriE, CanzonieroLMT, CiminiA, SensiSL (2018) Exenatide exerts cognitive effects by modulating the BDNF-TrkB neurotrophic axis in adult mice. Neurobiol Aging64, 33–43.
54.
HamiltonA, PattersonS, PorterD, GaultVA, HolscherC (2011) Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J Neurosci Res89, 481–489.
55.
MullinsRJ, MustapicM, ChiaCW, CarlsonO, GulyaniS, TranJ, LiY, MattsonMP, ResnickS, EganJM, GreigNH, KapogiannisD (2019) A pilot study of exenatide actions in Alzheimer’s disease. Curr Alzheimer Res16, 741–752.
56.
VilsbollT (2009) Liraglutide: A new treatment for type 2 diabetes. Drugs Today (Barc)45, 101–113.
57.
YuCJ, MaD, SongLL, ZhaiZN, TaoY, ZhangY, CaiLY, HouYH, ChenHY, WangL (2020) The role of GLP-1/GIP receptor agonists in Alzheimer’s disease. Adv Clin Exp Med29, 661–668.
58.
ZhengC, ZhouM, SunJ, XiongH, PengP, GuZ, DengY (2019) The protective effects of liraglutide on AD-like neurodegeneration induced by oxidative stress in human neuroblastoma SH-SY5Y cells. Chem Biol Interact310, 108688.
59.
BatistaAF, Forny-GermanoL, ClarkeJR, LyraESNM, Brito-MoreiraJ, BoehnkeSE, WinterbornA, CoeBC, LablansA, VitalJF, MarquesSA, MartinezAM, GralleM, HolscherC, KleinWL, HouzelJC, FerreiraST, MunozDP, De FeliceFG (2018) The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer’s disease. J Pathol245, 85–100.
60.
SharmaMK, JalewaJ, HolscherC (2014) Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress. J Neurochem128, 459–471.
61.
TalbotK, WangH-Y, BakshiK, TrojanowskiJ, ArnoldS (2011) The diabetes drug liraglutide ameliorates insulin resistance in the hippocampal formation of Alzheimer’s disease (AD) cases, Alzheimers Dement7, e65–e65.
62.
McCleanPL, ParthsarathyV, FaivreE, HolscherC (2011) The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease. J Neurosci31, 6587–6594.
63.
McCleanPL, HolscherC (2014) Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer’s disease. Neuropharmacology76 Pt A, 57–67.
64.
ParthsarathyV, HolscherC (2013) Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model, PLoS One8, e58784.
65.
HansenHH, FabriciusK, BarkholtP, NiehoffML, MorleyJE, JelsingJ, PykeC, KnudsenLB, FarrSA, VrangN (2015) The GLP-1 receptor agonist liraglutide improves memory function and increases hippocampal CA1 neuronal numbers in a senescence-accelerated mouse model of Alzheimer’s disease. J Alzheimers Dis46, 877–888.
66.
GejlM, GjeddeA, EgefjordL, MollerA, HansenSB, VangK, RodellA, BraendgaardH, GottrupH, SchachtA, MollerN, BrockB, RungbyJ (2016) In Alzheimer’s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: Randomized, placebo-controlled, double-blind clinical trial. Front Aging Neurosci8, 108.
67.
GejlM, BrockB, EgefjordL, VangK, RungbyJ, GjeddeA (2017) Blood-brain glucose transfer in Alzheimer’s disease: Effect of GLP-1 analog treatment. Sci Rep7, 17490.
68.
WatsonKT, WroolieTE, TongG, Foland-RossLC, FrangouS, SinghM, McIntyreRS, Roat-ShumwayS, MyorakuA, ReissAL, RasgonNL (2019) Neural correlates of liraglutide effects in persons at risk for Alzheimer’s disease. Behav Brain Res356, 271–278.
CaiHY, YangJT, WangZJ, ZhangJ, YangW, WuMN, QiJS (2018) Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer’s disease. Biochem Biophys Res Commun495, 1034–1040.
72.
CaiHY, WangZJ, HolscherC, YuanL, ZhangJ, SunP, LiJ, YangW, WuMN, QiJS (2017) Lixisenatide attenuates the detrimental effects of amyloid beta protein on spatial working memory and hippocampal neurons in rats. Behav Brain Res318, 28–35.
73.
CaiHY, HolscherC, YueXH, ZhangSX, WangXH, QiaoF, YangW, QiJS (2014) Lixisenatide rescues spatial memory and synaptic plasticity from amyloid beta protein-induced impairments in rats. Neuroscience277, 6–13.
74.
McCleanPL, HolscherC (2014) Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer’s disease. Neuropharmacology86, 241–258.
75.
HunterK, HolscherC (2012) Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci13, 33.
76.
ZhouM, ChenS, PengP, GuZ, YuJ, ZhaoG, DengY (2019) Dulaglutide ameliorates STZ induced AD-like impairment of learning and memory ability by modulating hyperphosphorylation of tau and NFs through GSK3beta. Biochem Biophys Res Commun511, 154–160.
77.
Cukierman-YaffeT, GersteinHC, ColhounHM, DiazR, Garcia-PerezLE, LakshmananM, BethelA, XavierD, ProbstfieldJ, RiddleMC, RydenL, AtissoCM, HallS, Rao-MelaciniP, BasileJ, CushmanWC, FranekE, KeltaiM, LanasF, LeiterLA, Lopez-JaramilloP, PiragsV, PogosovaN, RaubenheimerPJ, ShawJE, SheuWH, Temelkova-KurktschievT (2020) Effect of dulaglutide on cognitive impairment in type 2 diabetes: An exploratory analysis of the REWIND trial. Lancet Neurol19, 582–590.
78.
ChangYF, ZhangD, HuWM, LiuDX, LiL (2020) Semaglutide-mediated protection against Abeta correlated with enhancement of autophagy and inhibition of apoptosis. J Clin Neurosci81, 234–239.
79.
WangZJ, LiXR, ChaiSF, LiWR, LiS, HouM, LiJL, YeYC, CaiHY, HolscherC, WuMN (2023) Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer’s disease via the GLP-1R/SIRT1/GLUT4 pathway. Neuropharmacology240, 109716.
80.
BallardC, NørgaardCH, FriedrichS, MørchLS, GerdsT, MøllerDV, KnudsenLB, KvistK, ZinmanB, HolmE, Torp-PedersenC, HansenCT (2020) Liraglutide and semaglutide: Pooled post hoc analysis to evaluate risk of dementia in patients with type 2 diabetese. Alzheimers Dement16, 042909.
81.
AtriA, FeldmanH, HansenC, HonoreJ, JohannsenP, KnopF, PoulsenP, RaketL, SanoM, SoininenH, CummingsJ (2022) Evoke and evoke+: Design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating the neuroprotective effects of semaglutide in early Alzheimer’s disease, Alzheimers Dement18, e062415.
82.
McGovernSF, HunterK, HolscherC (2012) Effects of the glucagon-like polypeptide-1 analogue (Val8)GLP-1 on learning, progenitor cell proliferation and neurogenesis in the C57B/16 mouse brain. Brain Res1473, 204–213.
83.
LiH, CaoL, RenY, JiangY, XieW, LiD (2018) GLP-1 receptor regulates cell growth through regulating IDE expression level in Abeta1-42-treated PC12 cells. Biosci Rep38, BSR20171284.
84.
ZhangSX, CaiHY, MaXW, YuanL, ZhangJ, WangZJ, LiYF, QiJS (2017) GLP-1 analogue CJC-1131 prevents amyloid beta protein-induced impirments of spatial memory and synaptic plasticity in rats. Behav Brain Res326, 237–243.
85.
FaivreE, HolscherC (2013) Neuroprotective effects of D-Ala(2)GIP on Alzheimer’s disease biomarkers in an APP/PS1 mouse model. Alzheimers Res Ther5, 20.
86.
FaivreE, HolscherC (2013) D-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer’s disease mouse model. J Alzheimers Dis35, 267–283.
87.
DuffyAM, HolscherC (2013) The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer’s disease. Neuroscience228, 294–300.
88.
MaskeryM, GouldingEM, GenglerS, MelchiorsenJU, RosenkildeMM, HolscherC (2020) The dual GLP-1/GIP receptor agonist DA4-JC shows superior protective properties compared to the GLP-1 analogue liraglutide in the APP/PS1 mouse model of Alzheimer’s disease. Am J Alzheimers Dis Other Demen35, 1533317520953041.
89.
ShiL, ZhangZ, LiL, HolscherC (2017) A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model. Behav Brain Res327, 65–74.
90.
CaiHY, YangD, QiaoJ, YangJT, WangZJ, WuMN, QiJS, HolscherC (2021) A GLP-1/GIP dual receptor agonist DA4-JC effectively attenuates cognitive impairment and pathology in the APP/PS1/tau model of Alzheimer’s disease. J Alzheimers Dis83, 799–818.
91.
CaoY, HolscherC, HuMM, WangT, ZhaoF, BaiY, ZhangJ, WuMN, QiJS (2018) DA5-CH, a novel GLP-1/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP/PS1 mouse model of Alzheimer’s disease. Eur J Pharmacol827, 215–226.
92.
LiC, LiuW, LiX, ZhangZ, QiH, LiuS, YanN, XingY, HolscherC, WangZ (2020) The novel GLP-1/GIP analogue DA5-CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of AD, Brain Behav10, e01505.
93.
SallesGN, CalioML, HolscherC, Pacheco-SoaresC, PorcionattoM, LoboAO (2020) Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer’s disease. Neuropharmacology162, 107813.
94.
WangZJ, HanYF, ZhaoF, YangGZ, YuanL, CaiHY, YangJT, HolscherC, QiJS, WuMN (2020) A dual GLP-1 and Gcg receptor agonist rescues spatial memory and synaptic plasticity in APP/PS1 transgenic mice. Horm Behav118, 104640.
95.
PanagakiT, GenglerS, HolscherC (2018) The novel DA-CH3 dual incretin restores endoplasmic reticulum stress and autophagy impairments to attenuate Alzheimer-like pathology and cognitive decrements in the APPSWE/PS1DeltaE9 mouse model. J Alzheimers Dis66, 195–218.
96.
FriasJP, BastyrEJ3rd, VignatiL, TschopMH, SchmittC, OwenK, ChristensenRH, DiMarchiRD (2017) The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell Metab26, 343–352e342.
97.
FriasJP, NauckMA, VanJ, KutnerME, CuiX, BensonC, UrvaS, GimenoRE, MilicevicZ, RobinsD, HauptA (2018) Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: A randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet392, 2180–2193.
98.
LiT, JiaoJJ, HolscherC, WuMN, ZhangJ, TongJQ, DongXF, QuXS, CaoY, CaiHY, SuQ, QiJS (2018) A novel GLP-1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer’s disease. Hippocampus28, 358–372.
99.
LiT, JiaoJJ, SuQ, HolscherC, ZhangJ, YanXD, ZhaoHM, CaiHY, QiJS (2020) A GLP-1/GIP/Gcg receptor triagonist improves memory behavior, as well as synaptic transmission, neuronal excitability and Ca(2+) homeostasis in 3xTg-AD mice. Neuropharmacology170, 108042.
100.
ChoiIY, LeeJS, KimJK, ParkYJ, JungSY, KimYH, KwonSC (2017) Potent body weight loss and efficacy in a NASH animal model by a novel long-acting GLP-1/Glucagon/GIP triple-agonist (HM15211). American Diabetes Association’s 77th Scientific Session.
101.
TaiJ, LiuW, LiY, LiL, HolscherC (2018) Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer’s disease. Brain Res1678, 64–74.
102.
LiY, PerryT, KindyMS, HarveyBK, TweedieD, HollowayHW, PowersK, ShenH, EganJM, SambamurtiK, BrossiA, LahiriDK, MattsonMP, HofferBJ, WangY, GreigNH (2009) GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A106, 1285–1290.
103.
KimS, MoonM, ParkS (2009) Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson’s disease. J Endocrinol202, 431–439.
104.
BertilssonG, PatroneC, ZachrissonO, AnderssonA, DannaeusK, HeidrichJ, KortesmaaJ, MercerA, NielsenE, RonnholmH, WikstromL (2008) Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson’s disease. J Neurosci Res86, 326–338.
105.
ChenS, YuSJ, LiY, LeccaD, GlotfeltyE, KimHK, ChoiHI, HofferBJ, GreigNH, KimDS, WangY (2018) Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease. Sci Rep8, 10722.
106.
ZhangL, ZhangL, LiL, HolscherC (2018) Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson’s disease mouse model. Neuropeptides71, 70–80.
107.
LiY, LiuW, LiL, HolscherC (2017) D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson’s disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation. Eur J Pharmacol797, 162–172.
108.
KimWK, KimJA, KimSY, LeeS-H, BaeSM, ChoiIY, KimYH (2019) Effect of HM15211, a novel long-acting GLP-1/GIP/glucagon triple agonist in the neurodegenerative disease models. Diabetes68, 1810–1137.
